Abstract 5822
Background
The real life experience in clinical arena can be challenging for student nurses, to cope with the patients’ suffering, to provide care, to communicate with them and their caregivers as death approaches .It is essential to understand student nurses’ feelings when confronted a dying patient, so that specific training, consultation and empowerment give them prior to their clinical placement. However, there has been little research in Greece on student nurses’ experience when facing care of patients and their caregivers in the last days of life.The purpose of this study was to explore undergraduate student nurse’s experience facing death and dying of a patient during their clinical practice.
Methods
A qualitative, descriptive design was used. Qualitative data were collected in June 2018 from 4th -year nursing students’ of Nursing School of National and Kapodistrian University of Athens. Experiences were collected through written reflections to obtain data about their experience when cared for a serious ill patient and when delivered their care to a dying patient and their caregivers. A content analysis of their comments was carried out.
Results
From 101 undergraduated nurses 42 answered in open-ended question “Please describe the death experience of a patient during your clinical practice”. The response rate was 41,6%.The average age of the students was 22.Nursing students’ comments revealed concerns on handling the family/caregivers of the dying patient, their willingness to care for body of the dying, expressing their emotions such as sadness, describing death experience using medical terminology and using their previous personal experiences and knowledge to handle with . Thus five categories were emerged, the concept of “family/caregivers issues” “participation in the care of the dying” “description of the event using medical terminology”, “expressing emotions positive or negative” and “referring to their previous experience and knowledge” respectively.
Conclusions
Study’s findings highlighted the influence of knowledge, personal attitudes and clinical stressors that student nurses faced in a clinical practice when they were training in palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract